Medtronic Shares Are Trading Lower After the Company Announced the Six-month Results From the Full Cohort of the SPYRAL HTN-ON MED Trial. For the Primary Endpoint, RDN Did Not Demonstrate a Statistically Significant Reduction.
Medtronic Shares Are Trading Lower After the Company Announced the Six-month Results From the Full Cohort of the SPYRAL HTN-ON MED Trial. For the Primary Endpoint, RDN Did Not Demonstrate a Statistically Significant Reduction.
美敦力公司公布了SPYral HTN-on MED试验的全部六个月结果后，美敦力的股价下跌。对于主端点，RDN没有显示出统计意义上的显著减少。
Medtronic shares are trading lower after the company announced the six-month results from the full cohort of the SPYRAL HTN-ON MED trial. For the primary endpoint, RDN did not demonstrate a statistically significant reduction.
美敦力公布了SPYral HTN-on MED试验的全部队列6个月的结果后，该公司股价走低。对于主要终点，RDN没有显示出统计上显著的减少。
资讯热榜
更新时间